Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer

Showing results (251-260 of 41,508) with videos related to

Pageof 4,151
Sort By:
Cancer|February 4, 2009
Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland AustraliaAlan C Geller, Mark Elwood, Susan M Swetter, et al.
Cancer|February 4, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyMarc Peeters, Salvatore Siena, Eric Van Cutsem, et al.
Cancer|February 12, 2009
Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performanceRobert O Dillman, Kenneth Aaron, F Scott Heinemann, et al.
Cancer|February 12, 2009
Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trialsOlav Favier, Natacha Heutte, Aspasia Stamatoullas-Bastard, et al.
Cancer|February 7, 2009
Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studiesShao Hui Huang, David Hwang, Gina Lockwood, et al.
Cancer|February 7, 2009
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesionsXia Pu, Scott M Lippman, Hushan Yang, et al.
Cancer|February 7, 2009
Bevacizumab for recurrent alkylator-refractory anaplastic oligodendrogliomaMarc C Chamberlain, Sandra Johnston
Cancer|January 27, 2009
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment armsJohn A Glaspy, Veena Charu, Donghan Luo, et al.
Cancer|January 27, 2009
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541Electra Paskett, James Herndon, Kathleen Donohue, et al.
Cancer|January 27, 2009
Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survivalWen-Ting Liao, Xi Wang, Li-Hua Xu, et al.
Pageof 4,151

Showing results (251-260 of 41,508) with videos related to

Sort By:
Pageof 4,151
Cancer|February 4, 2009
Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland AustraliaAlan C Geller, Mark Elwood, Susan M Swetter, et al.
Cancer|February 4, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyMarc Peeters, Salvatore Siena, Eric Van Cutsem, et al.
Cancer|February 12, 2009
Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performanceRobert O Dillman, Kenneth Aaron, F Scott Heinemann, et al.
Cancer|February 12, 2009
Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trialsOlav Favier, Natacha Heutte, Aspasia Stamatoullas-Bastard, et al.
Cancer|February 7, 2009
Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studiesShao Hui Huang, David Hwang, Gina Lockwood, et al.
Cancer|February 7, 2009
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesionsXia Pu, Scott M Lippman, Hushan Yang, et al.
Cancer|February 7, 2009
Bevacizumab for recurrent alkylator-refractory anaplastic oligodendrogliomaMarc C Chamberlain, Sandra Johnston
Cancer|January 27, 2009
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment armsJohn A Glaspy, Veena Charu, Donghan Luo, et al.
Cancer|January 27, 2009
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541Electra Paskett, James Herndon, Kathleen Donohue, et al.
Cancer|January 27, 2009
Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survivalWen-Ting Liao, Xi Wang, Li-Hua Xu, et al.
Pageof 4,151